Search Results - "Catala, Eva"

Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment by Catalá, Eva, Iacoboni, Gloria, Barba, Pere

“…Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of patients with diffuse large B-cell lymphoma (DLBCL) who are refractory or…”
Get more information

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma by Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Corral, Lucía López, Morales, Rafael Hernani, Ortiz-Maldonado, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Domínguez, María Luisa Guerra, Pina, Jose Maria Sanchez, Mussetti, Alberto, Sancho, Juan Manuel, Bastos-Oreiro, Mariana, Catala, Eva, Delgado, Javier, Henriquez, Hugo Luzardo, Sanz, Jaime, Calbacho, María, Bailén, Rebeca, Carpio, Cecilia, Ribera, Jose Maria, Sureda, Anna, Briones, Javier, Hernandez-Boluda, Juan Carlos, Cebrián, Nuria Martínez, Martin, Jose Luis Diez, Martín, Alejandro, Barba, Pere

“…Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory…”
Get full text

Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy by Iacoboni, Gloria, Simó, Marc, Villacampa, Guillermo, Catalá, Eva, Carpio, Cecilia, Díaz-Lagares, Cándido, Vidal-Jordana, Ángela, Bobillo, Sabela, Marín-Niebla, Ana, Pérez, Ana, Jiménez, Moraima, Abrisqueta, Pau, Bosch, Francesc, Barba, Pere

“…Chimeric antigen receptor (CAR) T-cell therapy provides long-term remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Total…”
Get full text

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies by Jiménez, Moraima, Roldán, Elisa, Fernández-Naval, Candela, Villacampa, Guillermo, Martinez-Gallo, Mónica, Medina-Gil, Daniel, Peralta-Garzón, Soraya, Pujadas, Gemma, Hernández, Cristina, Pagès, Carlota, Gironella, Mercedes, Fox, Laura, Orti, Guillermo, Barba, Pere, Pumarola, Tomás, Cabirta, Alba, Catalá, Eva, Valentín, Mercedes, Marín-Niebla, Ana, Orfao, Alberto, González, Marcos, Campins, Magda, Ruiz-Camps, Isabel, Valcárcel, David, Bosch, Francesc, Hernández, Manuel, Crespo, Marta, Esperalba, Juliana, Abrisqueta, Pau

“…Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in…”
Get full text

Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma by Cabirta, Alba, Hidalgo-Gómez, Gloria, Marín-Niebla, Ana, Gallur, Laura, Saumell, Silvia, Castellví, Josep, Catalá, Eva, Blanco, Adoración, López-Andreoni, Laura, Montoro, María Julia, Navarrete, Mayda, Palacio-García, Carlos, Tazón-Vega, Bárbara, Bobillo, Sabela, Bosch, Francesc, Ortega, Margarita

Get full text

Neurotoxicity‐associated sinus bradycardia after chimeric antigen receptor T‐cell therapy by Catalá, Eva, Iacoboni, Gloria, Vidal‐Jordana, Ángela, Oristrell, Gerard, Carpio, Cecilia, Vilaseca, Andreu, Cabirta, Alba, Bosch, Francesc, Tintoré, Mar, Barba, Pere

“…The advent of chimeric antigen receptor (CAR) T‐cell therapy has changed the therapeutic landscape of relapsed/refractory aggressive B‐cell lymphomas. Cytokine…”
Get full text

Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy by Carbonell, Diego, Monsalvo, Silvia, Catalá, Eva, Pérez-Corral, Ana, Villegas, Carolina, Falero, Carmen, Ruano, Gloria, Martinez, Monica, Kwon, Mi, Muñoz-Martínez, Cristina, Díez-Martín, José Luis, Gayoso, Jorge, Anguita, Javier

“…Chimeric antigen receptor (CAR) T-cell therapy is increasingly used in patients affected by B-cell lymphoma and acute lymphoblastic leukemia. For logistical…”
Get full text

Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center by Carpio, Cecilia, Iacoboni, Gloria, Villacampa, Guillermo, Catalá, Eva, Bobillo, Sabela, Pérez, Ana, Jiménez, Moraima, Segura, Laura, Olivé, Mireia, Farriols, Anna, Abrisqueta, Pau, Valcárcel, David, Carreras, María Josep, Bosch, Francesc, Barba, Pere

Get full text

The Mid-Infrared Instrument for the James Webb Space Telescope, II: Design and Build by Wright, G. S., Wright, David, Goodson, G. B., Rieke, G. H., Aitink-Kroes, Gabby, Amiaux, J., Aricha-Yanguas, Ana, Azzollini, Ruymán, Banks, Kimberly, Barrado-Navascues, D., Belenguer-Davila, T., Bloemmart, J. A. D. L., Bouchet, Patrice, Brandl, B. R., Colina, L., Detre, Örs, Diaz-Catala, Eva, Eccleston, Paul, Friedman, Scott D., García-Marín, Macarena, Güdel, Manuel, Glasse, Alistair, Glauser, Adrian M., Greene, T. P., Groezinger, Uli, Grundy, Tim, Hastings, Peter, Henning, Th, Hofferbert, Ralph, Hunter, Faye, Jessen, N. C., Justtanont, K., Karnik, Avinash R., Khorrami, Mori A., Krause, Oliver, Labiano, Alvaro, Lagage, P.-O., Langer, Ulrich, Lemke, Dietrich, Lim, Tanya, Lorenzo-Alvarez, Jose, Mazy, Emmanuel, McGowan, Norman, Meixner, M. E., Morris, Nigel, Morrison, Jane E., Müller, Friedrich, Nø rgaard-Nielson, H.-U., Olofsson, Göran, O'Sullivan, Brian, Pel, J.-W., Penanen, Konstantin, Petach, M. B., Pye, J. P., Ray, T. P., Renotte, Etienne, Renouf, Ian, Ressler, M. E., Samara-Ratna, Piyal, Scheithauer, Silvia, Schneider, Analyn, Shaughnessy, Bryan, Stevenson, Tim, Sukhatme, Kalyani, Swinyard, Bruce, Sykes, Jon, Thatcher, John, Tikkanen, Tuomo, van Dishoeck, E. F., Waelkens, C., Walker, Helen, Wells, Martyn, Zhender, Alex

“…The Mid-InfraRed Instrument (MIRI) on the James Webb Space Telescope (JWST) provides measurements over the wavelength range 5 to 28.5 μm. MIRI has, within a…”
Get full text

P1401: IDENTIFICATION OF BIOMARKERS AND RISK FACTORS FOR IMMUNE EFFECTOR CELL‐ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN CD19‐DIRECTED CAR T‐CELL THERAPY: A RETROSPECTIVE MACHINE LEARNING‐BASED ANALYSIS by Gómez‐Llobell, Marina, Martínez García, María, Serra Smith, Carlos, Gómez Costas, Daniel, Oarbeascoa Royuela, Gillen, Carbonell, Diego, Anguita Velasco, Javier, Corral, Ana María Pérez, Pion, Marjorie, Astrid Pérez‐Fernández, Veronica, Fernández García, Isabel, Bastos Oreiro, Mariana, Fernández‐Caldas González, Paula, Gómez‐Centurión, Ignacio, Alarcón, Ana, Catalá, Eva, Conde, Diego, Gayoso, Jorge, Olmos, Pablo, Martínez Laperche, Carolina, García‐Domínguez, Jose, Fernández, Yolanda, Bailen, Rebeca, Kwon, MI

Get full text

Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP) by Jimenez, M Moraima, Bobillo, Sabela, Pérez, Ana, Arenas, Pamela, Cabirta, Alba, Catala, Eva, Rodriguez, Yva, Martin, Lucia, Serna, Angel, Bosch, Francesc, Valcárcel, David

“…INTRODUCTION For more than two decades, the treatment of aTTPconsisted of therapeutic plasma exchange (TPE) and immunosuppressive agents. The addition of…”
Get full text

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain by Cabirta, Alba, Izuzquiza, Macarena, Ruiz-Camps, Isabel, Valcarcel, David, Catala, Eva, Jimenez, M Moraima, Perez, Ana, Martin, Lucia, Rodriguez, Yva, Serna, Angel, Ruiz-Pace, Fiorella, Dienstmann, Rodrigo, Bobillo, Sabela, Carpio, Cecilia, Salamero, Olga, Abrisqueta, Pau, Bosch, Francesc

“…The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic raises many questions about the management of patients with significant…”
Get full text

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy by Iacoboni, Gloria, Simo, Marc, Villacampa, Guillermo, Catala, Eva, Carpio, Cecilia, Diaz-Lagares, Candido, Vidal-Jordana, Angela, Bobillo, Sabela, Marin-Niebla, Ana, Perez, Ana, Jiménez, Moraima, Abrisqueta, Pau, Valcárcel, David, Bosch, Francesc, Barba, Pere

“…Introduction Chimeric antigen receptor (CAR) T-cell therapy provides long-term remissions in a substantial proportion of patients with large B-cell lymphoma…”
Get full text

Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain by Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Lopez Corral, Lucia, Hernani, Rafael, Guerreiro, Manuel, Caballero, Ana Carolina, Ortiz-Maldonado, Valentín, Sanchez, Jose M., Paviglianiti, Annalisa, Sancho, Juan-Manuel, Bastos-Oreiro, Mariana, Oarbeascoa, Gillen, Martin Rojas, Reyes Maria, Catala, Eva, Delgado Serrano, Javier, Mussetti, Alberto, Sanz, Jaime, Calbacho, Maria, Bailen, Rebeca, Briones, Javier, Hernandez Boluda, Juan Carlos, Martin Garcia-Sancho, Alejandro, Diez-Martin, Jose L., Barba, Pere

“…Introduction: Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are the two autologous anti-CD19 chimeric antigen receptors T cells…”
Get full text

Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment by Catalá, Eva, Iacoboni, Gloria, Barba, Pere

“…Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of patients with diffuse large B-cell lymphoma (DLBCL) who are refractory or…”
Get full text

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo by Bailen, Rebeca, Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Lopez Corral, Lucia, Hernani, Rafael, Ortiz-Maldonado, Valentin, Guerreiro, Manuel, Caballero Gonzalez, Ana Carolina, Guerra, Luisa, Sanchez Pina, Jose Maria, Mussetti, Alberto, Sancho, Juan-Manuel, Bastos-Oreiro, Mariana, Catalá, Eva, Delgado Serrano, Javier, Luzardo Henriquez, Hugo Daniel, Caballer, Jaime Sanz, Calbacho, Maria, Carpio, Cecilia, Ribera, Josep-Maria, Torrent, Anna, Sureda Balari, Anna Maria, Briones, Javier, Hernandez Boluda, Juan Carlos, Martinez-Cibrian, Nuria, Martin Garcia-Sancho, Alejandro, Barba, Pere

“…Background: Median age at diagnosis of diffuse large B cell lymphoma (DLBCL) patients is 66 years; 40% of patients are diagnosed at an age greater than 70…”
Get full text